A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma
This is a prospective, open-label, non-randomized, multicenter study in adults, aged eighteen (18) or older, with newly-diagnosed or recurrent unresectable Stage III or Stage IV melanoma. A maximum of 18 subjects will be enrolled in Stage 1 of this study. (Stage 1 completed enrollment in June 2006.) A maximum of 39 subjects will be enrolled in Stage 2 of this study.
Melanoma
DRUG: INO-1001|DRUG: temozolomide
Maximum tolerated dose (MTD) or recommended Phase II dose of INO-1001 to be used in combination with TMZ, Length of study|Pharmacokinetic (PK) profile of intravenous INO-1001, Length of study|Safety and tolerability of combined therapy with oral temozolomide (TMZ) and intravenous INO-1001, Length of study
Safety of repeat dosing, Length of study|Pharmacodynamic (PD) activity of intravenous INO-1001, Length of study|Response, Length of study|Progression-free survival, Length of study|Overall survival, Length of study
This is a prospective, open-label, non-randomized, multicenter study in adults, aged eighteen (18) or older, with newly-diagnosed or recurrent unresectable Stage III or Stage IV melanoma. A maximum of 18 subjects will be enrolled in Stage 1 of this study. (Stage 1 completed enrollment in June 2006.) A maximum of 39 subjects will be enrolled in Stage 2 of this study.